This system enables responsive drug release in the acidic tumor microenvironment and co-delivers a miR-620 inhibitor to suppress the IRF2BP2 axis, resulting in dual inhibition of tumor cell proliferation and induction of apoptosis [118]. The gene discussed is IRF2BP2; the disease is neoplasm.